A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Triamcinolone (Primary)
- Indications Retinal oedema; Uveitis
- Focus Registrational; Therapeutic Use
- Acronyms PEACHTREE
- Sponsors Clearside Biomedical
- 01 Oct 2023 Post-hoc analysis results published in the Ocular Immunology and Inflammation,
- 18 Nov 2022 Results of Integrated Analysis of Two Phase 3 Studies(NCT02595398 and NCT03097315) for triamcinolone acetonide injectable suspension for suprachoroidal use in the treatment of macular edema secondary to noninfectious uveitis published in the Ophthalmology and Therapy
- 04 Oct 2022 According to Clearside Biomedical media release, data from this trial presented during the annual meeting of the American Academy of Ophthalmology (AAO).